The impact of hepatitis B (HBV) and C (HCV) on patient survival after kidney transplantation is controversial. The aims of this study were (1) to assess the independent prognostic values of HBsAg and anti-HCV in a large renal transplant population, (2) to compare infected patients with noninfected patients matched for factors possibly associated with graft and patient survival, and (3) to assess the prognostic value of biopsy-proven cirrhosis. Eight hundred thirty-four transplanted patients were included: 128 with positive HBsAg (group I), 216 with positive anti-HCV (group II), and 490 without serological markers of HBV and HCV (group III). Fifteen percent and 29% of patients were HBsAg-positive and anti-HCV-positive, respectively. Tenyear survivals of group I (55 ؎ 6%) and group II (65 ؎ 5%) were significantly lower than survival of group III (80 ؎ 3%, P F .001). At 10 years, among overall patients with HCV screening (n ؍ 834), four variables had independent prognostic values in patient survival: age at transplantation (P F .0001), year of transplantation (P ؍ .02), biopsyproven cirrhosis (P ؍ .03), and presence of HCV antibodies (P ؍ .02). In the case control study, comparison of infected patients with their matched control patients showed that age at transplantation (P F .05), HBsAg (P ؍ .005), and anti-HCV (P ؍ .005) were independent prognostic factors. HCV, biopsy-proven cirrhosis, and age are independent prognostic factors of 10-year survival in patients with kidney grafts. The case-control study showed that anti-HCV and HBsAg were independently associated with patient and graft survivals. In infected patients, a routine liver histological analysis would improve selection of patients for renal transplantation.(HEPATOLOGY 1999;29:257-263.) Improvement in renal transplantation in the past 25 years has been the result of better immunosuppression, organ preservation, and patient selection. 1,2 In patients receiving a kidney transplant, chronic liver disease remains a major problem and leads to enhanced morbidity and mortality. 3 In these cases, HBV and HCV infection are the main causes of liver injury. [4][5][6] In transplanted patients, immunosuppressive therapy increases viral replication, and disappearance of anti-HCV antibodies is observed in 20% of cases. [5][6][7][8] Paradoxically, no consensus is available concerning the prognostic influence of HBV and HCV infections on graft and patient survival.Although liver injury progression seems to be greater in transplanted patients than in immunocompetent patients, the influence of HBV on patient and graft survival remains controversial. 4,9-14 These contradictory results may be attributed to the wide heterogeneity of characteristics of patients at the time of transplantation.In kidney transplanted patients, prevalence of HCV infection ranged from 20% to 30%. [15][16][17][18] Now, since the advent of routine HBV vaccination, most hepatic diseases in kidney transplantation are mainly a result of HCV virus infection. 19,20 The most frequent risk facto...
RI~SUMI~La fracture de verge est un accident relativement rare. Nous rapportons 12 cas de fracture de verge collig6s sur une p6riode de 17 ans.Le traumatisme causal 6tait le faux pas du coit (n=8) ou la manipulation intempestive de la verge en 6rection (n--4). La symptomatologie clinique a 6t6 marqu6e par la d6formation de la verge (n=9) et la douleur lors du traumatisme (n=7). Dans 1 cas il existait une rupture ur6trale associ6e. Tousles patients ont 6t6 trait6s chirurgicalement avec de bons r6sultats dans 11 cas sur le plan cosm6tique et fonctionnel sans aucune dys6rection. Les auteurs passent en revue les diff6rents moyens diagnostiques et soulignent l'importance d'une r6paration chirurgicale en urgence dans les fractures de verge.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.